Summary

Kidney Cancer Diagnostics Market – Scope of Report
TMR’s report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.

The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.

Key Questions Answered in Global kidney cancer diagnostics Market Report
• What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global kidney cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Kidney Cancer Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Kidney Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Platform-based Products
6.3.2. Instrument-based Products
6.3.3. Kits and Reagents
6.3.4. Others (Consumables, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Test Type, 2020-2034
7.3.1. Biopsy
7.3.2. Imaging Tests
7.3.3. Blood Tests
7.3.4. Others (Genetic Testing, etc.)
7.4. Market Attractiveness, by Test Type
8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Cancer Stage, 2020-2034
8.3.1. Stage 1
8.3.2. Stage 2
8.3.3. Stage 3
8.3.4. Stage 4
8.4. Market Attractiveness, By Cancer Stage
9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Tumor Type, 2020-2034
9.3.1. Renal Cell Carcinoma
9.3.2. Clear Cell Carcinoma
9.3.3. Non-clear Cell Carcinoma
9.4. Market Attractiveness, by Tumor Type
10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Tumor Type, 2020-2034
10.3.1. Fluorescent In Situ Hybridization
10.3.2. Next Generation Sequencing
10.3.3. Fluoroimmunoassay
10.3.4. Comparative Genomic Hybridization
10.3.5. Others (Immunohistochemical, etc.)
10.4. Market Attractiveness, by Tumor Type
11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user
11.1. Introduction and Definitions
11.2. Key Findings/Developments
11.3. Market Value Forecast, by End-user, 2020-2034
11.3.1. Hospitals
11.3.2. Cancer Research Centers
11.3.3. Oncology Clinics
11.3.4. Diagnostic Centers
11.3.5. Ambulatory Surgery Centers
11.3.6. Others (Research Institutes, etc.)
11.4. Market Attractiveness, by End-user
12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2020-2034
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness, by Region
13. North America Kidney Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2020-2034
13.2.1. Platform-based Products
13.2.2. Instrument-based Products
13.2.3. Kits and Reagents
13.2.4. Others (Consumables, etc.)
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Test Type, 2020-2034
13.4.1. Biopsy
13.4.2. Imaging Tests
13.4.3. Blood Tests
13.4.4. Others (Genetic Testing, etc.)
13.5. Market Attractiveness, by Test Type
13.6. Market Value Forecast, By Cancer Stage, 2020-2034
13.6.1. Stage 1
13.6.2. Stage 2
13.6.3. Stage 3
13.6.4. Stage 4
13.7. Market Attractiveness, By Cancer Stage
13.8. Market Value Forecast, by Tumor Type, 2020-2034
13.8.1. Renal Cell Carcinoma
13.8.2. Clear Cell Carcinoma
13.8.3. Non-clear Cell Carcinoma
13.9. Market Attractiveness, by Tumor Type
13.10. Market Value Forecast, by Technology 2020-2034
13.10.1. Fluorescent In Situ Hybridization
13.10.2. Next Generation Sequencing
13.10.3. Fluoroimmunoassay
13.10.4. Comparative Genomic Hybridization
13.10.5. Others (Immunohistochemical, etc.)
13.11. Market Attractiveness, by Technology
13.12. Market Value Forecast, by End-user, 2020-2034
13.12.1. Hospitals
13.12.2. Cancer Research Centers
13.12.3. Oncology Clinics
13.12.4. Diagnostic Centers
13.12.5. Ambulatory Surgery Centers
13.12.6. Others (Research Institutes, etc.)
13.13. Market Attractiveness, by End-user
13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
13.14.1. U.S.
13.14.2. Canada
13.15. Market Attractiveness Analysis
13.15.1. By Product Type
13.15.2. By Test Type
13.15.3. By Cancer Stage
13.15.4. By Tumor Type
13.15.5. By End-user
13.15.6. By Country
14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2020-2034
14.2.1. Platform-based Products
14.2.2. Instrument-based Products
14.2.3. Kits and Reagents
14.2.4. Others (Consumables, etc.)
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Test Type, 2020-2034
14.4.1. Biopsy
14.4.2. Imaging Tests
14.4.3. Blood Tests
14.4.4. Others (Genetic Testing, etc.)
14.5. Market Attractiveness, by Test Type
14.6. Market Value Forecast, By Cancer Stage, 2020-2034
14.6.1. Stage 1
14.6.2. Stage 2
14.6.3. Stage 3
14.6.4. Stage 4
14.7. Market Attractiveness, By Cancer Stage
14.8. Market Value Forecast, by Tumor Type, 2020-2034
14.8.1. Renal Cell Carcinoma
14.8.2. Clear Cell Carcinoma
14.8.3. Non-clear Cell Carcinoma
14.9. Market Attractiveness, by Tumor Type
14.10. Market Value Forecast, by Technology, 2020-2034
14.10.1. Fluorescent In Situ Hybridization
14.10.2. Next Generation Sequencing
14.10.3. Fluoroimmunoassay
14.10.4. Comparative Genomic Hybridization
14.10.5. Others (Immunohistochemical, etc.)
14.11. Market Attractiveness, by Technology
14.12. Market Value Forecast, by End-user, 2020-2034
14.12.1. Hospitals
14.12.2. Cancer Research Centers
14.12.3. Oncology Clinics
14.12.4. Diagnostic Centers
14.12.5. Ambulatory Surgery Centers
14.12.6. Others (Research Institutes, etc.)
14.13. Market Attractiveness, by End-user
14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
14.14.1. Germany
14.14.2. U.K.
14.14.3. France
14.14.4. Italy
14.14.5. Spain
14.14.6. Rest of Europe
14.15. Market Attractiveness Analysis
14.15.1. By Product Type
14.15.2. By Test Type
14.15.3. By Cancer Stage
14.15.4. By Tumor Type
14.15.5. By End-user
14.15.6. By Country/Sub-region
15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2020-2034
15.2.1. Platform-based Products
15.2.2. Instrument-based Products
15.2.3. Kits and Reagents
15.2.4. Others (Consumables, etc.)
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Test Type, 2020-2034
15.4.1. Biopsy
15.4.2. Imaging Tests
15.4.3. Blood Tests
15.4.4. Others (Genetic Testing, etc.)
15.5. Market Attractiveness, by Test Type
15.6. Market Value Forecast, By Cancer Stage, 2020-2034
15.6.1. Stage 1
15.6.2. Stage 2
15.6.3. Stage 3
15.6.4. Stage 4
15.7. Market Attractiveness, By Cancer Stage
15.8. Market Value Forecast, by Tumor Type, 2020-2034
15.8.1. Renal Cell Carcinoma
15.8.2. Clear Cell Carcinoma
15.8.3. Non-clear Cell Carcinoma
15.9. Market Attractiveness, by Tumor Type
15.10. Market Value Forecast, by Technology 2020-2034
15.10.1. Fluorescent In Situ Hybridization
15.10.2. Next Generation Sequencing
15.10.3. Fluoroimmunoassay
15.10.4. Comparative Genomic Hybridization
15.10.5. Others (Immunohistochemical, etc.)
15.11. Market Attractiveness, by Technology
15.12. Market Value Forecast, by End-user, 2020-2034
15.12.1. Hospitals
15.12.2. Cancer Research Centers
15.12.3. Oncology Clinics
15.12.4. Diagnostic Centers
15.12.5. Ambulatory Surgery Centers
15.12.6. Others (Research Institutes, etc.)
15.13. Market Attractiveness, by End-user
15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
15.14.1. China
15.14.2. Japan
15.14.3. India
15.14.4. Australia & New Zealand
15.14.5. Rest of Asia Pacific
15.15. Market Attractiveness Analysis
15.15.1. By Product Type
15.15.2. By Test Type
15.15.3. By Cancer Stage
15.15.4. By Tumor Type
15.15.5. By End-user
15.15.6. By Country/Sub-region
16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Type, 2020-2034
16.2.1. Platform-based Products
16.2.2. Instrument-based Products
16.2.3. Kits and Reagents
16.2.4. Others (Consumables, etc.)
16.3. Market Attractiveness, by Product Type
16.4. Market Value Forecast, by Test Type, 2020-2034
16.4.1. Biopsy
16.4.2. Imaging Tests
16.4.3. Blood Tests
16.4.4. Others (Genetic Testing, etc.)
16.5. Market Attractiveness, by Test Type
16.6. Market Value Forecast, By Cancer Stage, 2020-2034
16.6.1. Stage 1
16.6.2. Stage 2
16.6.3. Stage 3
16.6.4. Stage 4
16.7. Market Attractiveness, By Cancer Stage
16.8. Market Value Forecast, by Tumor Type, 2020-2034
16.8.1. Renal Cell Carcinoma
16.8.2. Clear Cell Carcinoma
16.8.3. Non-clear Cell Carcinoma
16.9. Market Attractiveness, by Tumor Type
16.10. Market Value Forecast, by Technology, 2020-2034
16.10.1. Fluorescent In Situ Hybridization
16.10.2. Next Generation Sequencing
16.10.3. Fluoroimmunoassay
16.10.4. Comparative Genomic Hybridization
16.10.5. Others (Immunohistochemical, etc.)
16.11. Market Attractiveness, by Technology
16.12. Market Value Forecast, by End-user, 2020-2034
16.12.1. Hospitals
16.12.2. Cancer Research Centers
16.12.3. Oncology Clinics
16.12.4. Diagnostic Centers
16.12.5. Ambulatory Surgery Centers
16.12.6. Others (Research Institutes, etc.)
16.13. Market Attractiveness, by End-user
16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
16.14.1. Brazil
16.14.2. Mexico
16.14.3. Rest of Latin America
16.15. Market Attractiveness Analysis
16.15.1. By Product Type
16.15.2. By Test Type
16.15.3. By Cancer Stage
16.15.4. By Tumor Type
16.15.5. By End-user
16.15.6. By Country/Sub-region
17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Product Type, 2020-2034
17.2.1. Platform-based Products
17.2.2. Instrument-based Products
17.2.3. Kits and Reagents
17.2.4. Others (Consumables, etc.)
17.3. Market Attractiveness, by Product Type
17.4. Market Value Forecast, by Test Type, 2020-2034
17.4.1. Biopsy
17.4.2. Imaging Tests
17.4.3. Blood Tests
17.4.4. Others (Genetic Testing, etc.)
17.5. Market Attractiveness, by Test Type
17.6. Market Value Forecast, By Cancer Stage, 2020-2034
17.6.1. Stage 1
17.6.2. Stage 2
17.6.3. Stage 3
17.6.4. Stage 4
17.7. Market Attractiveness, By Cancer Stage
17.8. Market Value Forecast, by Tumor Type, 2020-2034
17.8.1. Renal Cell Carcinoma
17.8.2. Clear Cell Carcinoma
17.8.3. Non-clear Cell Carcinoma
17.9. Market Attractiveness, by Tumor Type
17.10. Market Value Forecast, by Technology, 2020-2034
17.10.1. Fluorescent In Situ Hybridization
17.10.2. Next Generation Sequencing
17.10.3. Fluoroimmunoassay
17.10.4. Comparative Genomic Hybridization
17.10.5. Others (Immunohistochemical, etc.)
17.11. Market Attractiveness, by Technology
17.12. Market Value Forecast, by End-user, 2020-2034
17.12.1. Hospitals
17.12.2. Ambulatory Surgical Centers
17.12.3. Nursing Centers
17.12.4. Others (Long Term Care Centers, etc.)
17.13. Market Attractiveness, by End-user
17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
17.14.1. GCC Countries
17.14.2. South Africa
17.14.3. Rest of Middle East & Africa
17.15. Market Attractiveness Analysis
17.15.1. By Product Type
17.15.2. By Test Type
17.15.3. By Cancer Stage
17.15.4. By Tumor Type
17.15.5. By End-user
17.15.6. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
18.2. Market Share Analysis, by Company (2023)
18.3. Company Profiles
18.3.1. Siemens Healthineers
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Koninklijke Philips N.V.
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. FUJIFILM Holdings Corporation
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Grail
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Laboratory Corporation of America Holdings
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.6. Thermo Fisher Scientific
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Myriad Genetics, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Canon Medical Systems Corporation
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. QIAGEN N.V.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Illumina, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Ambry Genetics
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Invitae Corp.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
18.3.13. Centogene N.V.
18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.13.2. Product Portfolio
18.3.13.3. Financial Overview
18.3.13.4. SWOT Analysis
18.3.13.5. Strategic Overview